Intrexon | XON - Net Income


Intrexon reported $-20.32M in Net Income for its fiscal quarter ending in June of 2023.





Net Income Change Date
Agenus USD -10.63M 74.49M Dec/2025
Alaunos Therapeutics USD -1.16M 108K Sep/2025
Amgen USD 1.82B 486M Mar/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
MacroGenics USD -14.16M 30.98M Dec/2025
MannKind USD -15.95M 23.93M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Novartis USD 3.16B 747M Mar/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Thermo Fisher Scientific USD 1.65B 313M Mar/2026
Veracyte USD 28.71M 12.44M Mar/2026
Xencor USD -128.92M 122.26M Mar/2026